Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis
Status:
Completed
Trial end date:
2020-01-02
Target enrollment:
Participant gender:
Summary
Primary Objective:
To determine the dose-response relationship for SAR442168 to reduce the number of new active
brain lesions.
Secondary Objectives:
- To evaluate efficacy of SAR442168 on disease activity as assessed by imaging measures.
- To evaluate the safety and tolerability of SAR442168.